Chapter 18: Bipolar Medications

Lithium remains the cornerstone therapeutic agent, functioning as a gold-standard mood stabilizer through effects on intracellular signaling pathways and neurotransmitter regulation, though its narrow therapeutic window necessitates careful blood level monitoring and regular laboratory assessment. Beyond lithium, anticonvulsant medications including valproate, carbamazepine, and lamotrigine provide alternative or adjunctive options, each with distinct pharmacodynamic profiles and efficacy patterns across manic, depressive, and maintenance phases of treatment. Second-generation antipsychotics have become increasingly central to bipolar management, particularly for acute manic episodes and treatment-resistant presentations, with different agents demonstrating variable effectiveness for manic versus depressive symptomatology. The chapter addresses a critical clinical paradox: the potential for antidepressants, particularly selective serotonin reuptake inhibitors, to precipitate or exacerbate manic episodes in bipolar populations, making their use controversial and requiring careful consideration alongside mood-stabilizing medication. Treatment complexity intensifies with presentations of rapid cycling, where mood episodes occur with unusual frequency, and treatment-resistant bipolar disorder, both of which demand sophisticated medication selection and combination strategies. Patient medication adherence emerges as a fundamental challenge in long-term bipolar management, as many individuals discontinue pharmacotherapy despite demonstrated relapse risk, driven by side effect burdens, cognitive effects, or ambivalence about treatment necessity. The chapter emphasizes that optimal bipolar care typically requires polypharmacy approaches that strategically combine mood stabilizers, antipsychotics, and occasionally antidepressants, with selection guided by individual symptom profiles, prior treatment responses, comorbidities, and tolerability considerations. Understanding both the neurobiological rationale for each medication class and the practical barriers to effective implementation prepares clinicians to support more stable, sustained outcomes in bipolar disorder.